Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash & Equivalents (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Cash & Equivalents data on record, last reported at $150.1 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 285.26% year-over-year to $150.1 million; the TTM value through Sep 2025 reached $150.1 million, up 285.26%, while the annual FY2024 figure was $70.6 million, 70.47% down from the prior year.
  • Cash & Equivalents reached $150.1 million in Q3 2025 per COLL's latest filing, up from $117.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $283.7 million in Q2 2023 and bottomed at $39.0 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $169.9 million, with a median of $173.7 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 84.93% in 2024, then surged 285.26% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $186.4 million in 2021, then fell by 6.83% to $173.7 million in 2022, then surged by 37.57% to $238.9 million in 2023, then crashed by 70.47% to $70.6 million in 2024, then skyrocketed by 112.71% to $150.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $150.1 million in Q3 2025, $117.3 million in Q2 2025, and $96.2 million in Q1 2025.